Parmedics, Inc.
Temecula, CA Doing business as Biotechnology
- UEI
- SYC7ELNKMLE6
- CAGE
- 8PS26
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 41593 Winchester Rd Suite 200, Temecula, CA 92590, USA
- Website
- parmedics.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Kevirx Inc. | Charlottesville, VA | — |
| Adepthera LLC | Palo Alto, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Nupeak Therapeutics Inc. | Clayton, MO | — |
| Cornovus Pharmaceuticals Inc. | New Haven, CT | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Medchem Partners LLC | Lexington, MA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
About the company
Parmedics, Inc., doing business as Biotechnology, is a for-profit and woman-owned biotechnology company registered with SAM.gov to receive federal grant awards. The company is focused on developing small molecule antagonists targeting the protease-activated receptor-2 (PAR2) for various therapeutic applications.
Parmedics, Inc. has received several federal grant awards from the National Institutes of Health (NIH), primarily from the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Neurological Disorders and Stroke (NINDS). These awards support the development of PAR2 antagonists as potential oral therapeutics for asthma and migraine pain. Notably, the company has developed novel PAR2 antagonists, including C937 and C938, for asthma treatment, and has identified lead compounds that can reduce migraine-like pain in animal models without crossing the blood-brain barrier. Additionally, Parmedics has been awarded grants to conduct pharmacokinetic and efficacy studies of the aerosolized PAR2 antagonist C781 for asthma treatment, optimize its production and formulation, and perform IND-enabling preclinical studies. The company has also received funding to develop small molecule PAR2 antagonists, such as C391 and C781, and demonstrate their effectiveness in limiting allergen-induced asthma indicators in preclinical mouse models.
Quick answers
Is Parmedics, Inc. registered in SAM.gov?
Yes. Parmedics, Inc.'s SAM.gov registration is active through July 24, 2027.
What is Parmedics, Inc.'s most recent federal award?
Parmedics, Inc.'s most recent federal grant award is Development of small molecule protease-activated-receptor-2 antagonists as oral asthma therapeutics - lay abstract… (R41HL169048), from National Heart Lung and Blood Institute (NIH), on September 15, 2023.
On GovTribe
See Parmedics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors